λ‘λΌμ ν
λ‘λΌμ νμ κ°λ ₯ν μ€κ° μμ©ν **λ²€μ‘°λμμ νκ³ μ½λ¬Ό**λ‘, μμνμμλ μ£Όλ‘ νλ μ₯μ λ₯Ό μν νλΆμμ λ° **κ°μ§ μ€μ²©μ¦** μΉλ£ μ λμμ νμ λ체μ λ‘ μ¬μ©λ©λλ€γ > **μμ μμ :** λμμ νκ³Ό λ¬λ¦¬ λ‘λΌμ νμ νμ± μ€κ° λμ¬ μ°λ¬Όμ νμ±νμ§ μκ³ μ§μ κΈλ£¨μΏ λ‘ μ° ν¬ν© κ³Όμ μ κ±°μΉ©λλ€. μ΄λ λ Έλ Ή, λΉλ§ λλ κ° κΈ°λ₯μ΄ μ νλ νμμκ² ν¨μ¬ μμ ν μ νμ΄ λ©λλ€. - **λ€μν ν¬μ¬ κ²½λ‘:** λΉκ° λ΄, κ·Όμ‘ λ΄, μ€ν/λ³Ό μ λ§ λ± λ€μν κ²½λ‘λ‘ ν¬μ¬ν μ μμ΄ κ°μ μ΄λ λ³μμμμ μκΈ λ°μ κ΄λ¦¬μ λ§€μ° λ€μ©λλ‘ νμ©λ©λλ€. - **μμ© μκ°:** λμμ νλ§νΌ ν¨κ³Όμ μΈ κ²μΌλ‘ 보μ΄λ©°, νκ²½λ ¨ μμ© μ§μ μκ°μ΄ λ κΈΈ μ μμ΅λλ€(λ¨, κ°μμλ λͺ νν μ μ¦λμ§ μμ).
μμ© κΈ°μ : Lorazepam acts as a **positive allosteric modulator** at the **GABA-A receptor**. - It binds to the benzodiazepine site on the GABA-A receptor complex β enhances the affinity of the receptor for the inhibitory neurotransmitter **gamma-aminobutyric acid (GABA)**. - This increases the frequency of chloride channel openings β influx of chloride ions β **hyperpolarization** of the neuronal membrane β decreased neuronal excitability. - This widespread CNS depression primarily affects the subcortical levels (limbic, thalamic, and hypothalamic), yielding anxiolytic, sedative, skeletal muscle relaxant, and anticonvulsant effects. - Other postulated mechanisms include antagonism of serotonin and diminished release or turnover of acetylcholine in the CNS.
λλ¬Ό μ’ λ³ μ©λ
- Fears/anxiety Β· 0.03-0.08 mg/kg PO q12h Β· PO Β· q12h Β· The lowest dose and frequency that alleviate the fear should be used
- Fears, anxieties, phobias Β· 0.125 mg-0.25 mg total dose (ΒΌ-Β½ of a 0.5 mg tablet) once to twice a day Β· PO Β· q12-24h Β· May be used on an as needed basis
- Anxiolytic Β· 0.05-0.25 mg/kg PO q12-24h Β· PO Β· q12-24h
- Short-term management of anxiety disorders Β· 0.02-0.1 mg/kg Β· PO Β· q12-24h Β· Short-term Β· Start at the lower end of the dose range and gradually increase. Monitor closely for signs of hepatotoxicity.
- Status epilepticus (alternative to diazepam) Β· 0.2 mg/kg IV, IM or intranasal once Β· IV/IM/intranasal Β· once
- Status epilepticus Β· 0.2 mg/kg IV once, followed by a bolus IV loading dose of levetiracetam at 60 mg/kg Β· IV Β· once
- Fears, anxieties, phobias Β· 0.02-0.1 mg/kg PO once daily to three times a day Β· PO Β· q8-24h Β· May be used on an as needed basis
- Anxiolytic Β· 0.05-0.25 mg/kg PO q12-24h Β· PO Β· q12-24h
- Fears/anxiety Β· 0.02-0.5 mg/kg PO q8h Β· PO Β· q8h Β· The lowest dose and frequency that alleviate the fear should be used
- Fears, anxieties, phobias, aversions Β· 0.02-0.1 mg/kg q8-24h Β· PO Β· q8-24h Β· Minimally sedating, may require 4 weeks to peak effect
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Hypersensitivity to benzodiazepines
- Severe respiratory insufficiency (unless mechanically ventilated)
- Glaucoma
- Significant liver disease
- Significant kidney disease
- Pregnant animals
- Lactating animals
μ΄μλ°μ
- Increased appetite
- Aggression
- Increased activity/excitement (paradoxical reaction)
- Vocalization
- Ataxia
- Somnolence
- Lethargy
- Disinhibition (potential emergence of aggression)
- Drowsiness
- Mild transient incoordination (ataxia)
- Tremor and inappetence (associated with acute withdrawal)
μ½λ¬Ό μνΈμμ©
- CNS Depressants (opiates, barbiturates, sedatives, anticonvulsants) Β· Additive CNS effects
- Probenecid Β· Decreased renal clearance of lorazepam
- Scopolamine Β· Increased CNS depression, irrational behavior
- Theophylline Β· Decreased sedation from lorazepam
- Valproate Β· Increased lorazepam serum concentration
- Itraconazole Β· Inhibits the metabolism of lorazepam, potentially leading to increased plasma concentrations and prolonged sedation. Β· moderate
- Ketoconazole Β· May inhibit the metabolism of lorazepam, increasing the risk of toxicity. Β· moderate
- Other CNS Depressants Β· Additive CNS depression and sedation. Β· major
λͺ¨λν°λ§
- Clinical efficacy (seizure control or anxiety reduction)
- Adverse effects (CNS depression, paradoxical excitation, ataxia)
- Behavioral changes (watch for paradoxical aggression or extreme sedation)
- Liver enzymes (ALT, AST, ALP, Bilirubin), especially in cats
- Appetite and water intake
κ³Όμ©λ
Overdoses of lorazepam are generally limited to **CNS depression** (confusion, lethargy, somnolence, decreased reflexes). - **Severe Toxicity:** Very large overdoses can cause ataxia, hypotension, coma, and rarely death. - **Treatment:** Standard protocols for removing/binding the drug in the gut (if orally ingested) and supportive systemic measures. Forced diuresis with IV fluids/electrolytes and mannitol may enhance excretion in patients with normal renal function. - **Antidote:** **Flumazenil** may be considered for adjunctive treatment of serious overdoses, but it does not replace supportive therapy. *Caution: Flumazenil is not recommended in patients with seizure disorders as it may induce seizures.* - **Note:** Analeptic agents (CNS stimulants like caffeine) are generally not recommended.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.